Background: Alcoholic gastritis, a superficial erosive disease of the stomach, is a common manifestation of risky alcohol use. In contrast, cannabis which is frequently co-used with alcohol suppresses gastric acidity and might counteract the deleterious effect of alcohol on the gastric mucosa. However, no clinical study has examined the impact of cannabis use on the development of alcoholic gastritis among risky alcohol users.
A S A MAJOR risk factor in over 200 diseases (World Health Organization, 2004 , risky alcohol drinking is the most common substance use disorder, with a prevalence of over 18.4% among adults (Peacock et al., 2018) . Impaired leukocyte-mediated bacteria clearance, neurologic disorders, and liver disease are just a few of the chronic disorders associated with risky alcohol drinking (Rehm et al., 2014; World Health Organization, 2014) . Risky alcohol drinking also presents with a large spectrum of acute gastrointestinal illnesses such as acute pancreatitis, acute alcoholic hepatitis, and acute gastritis (Bujanda, 2000) . Notably, 70% of ingested alcohol is absorbed in the stomach and 30% in the small intestine; similarly, 10% is metabolized by gastric alcohol dehydrogenase enzyme while the remaining 90% is by the liver (Vonghia et al., 2008) . As a result, the stomach and the liver are the organs most exposed and affected by risky alcohol consumption. In the stomach, alcohol's corrosive action on the mucosa, alcohol-induced hypergastrinemia resulting in elevated gastric acid secretion, and impaired gastric muscle motility, all precipitate alcoholic gastritis (Bujanda, 2000; Chari et al., 1993; Franke et al., 2005; Kvietys et al., 1990; Laine and Weinstein, 1988; Singer et al., 1987; Singh et al., 2015) . Clinically, alcoholic gastritis presents with abdominal discomfort, nausea, vomiting, and some complications such as dehydration and electrolyte abnormalities (Elseweidy, 2017) . Most cases are mild to moderate, but the severity of symptoms can sometimes warrant the hospitalization of patients (Elseweidy, 2017) .
Cannabinoids which represent one of the main active ingredients in cannabis (marijuana) have been shown to regulate numerous physiological systems in the body (Di Marzo et al., 2004) . They are predominantly associated with antiinflammatory effects in the gastrointestinal tract and the suppression of chronic inflammation in alcoholic and nonalcoholic cirrhosis (DiPatrizio, 2016; Goyal et al., 2017; Gyires and Z adori, 2016; Patsenker and Stickel, 2016; Tam et al., 2011) . In murine disease models, cannabinoids have been shown to suppress gastrin production, gastric acid secretion, mucosal inflammation, and mucosal ulceration (Abdel-Salam, 2016; Abdel-Salam et al., 2015; Adami et al., 2002; Coruzzi et al., 1999; Sofia et al., 1978) . Therefore, we surmised that cannabis use by humans might have modulatory effects on the gastric mucosa. The paucity of human studies on the effects of cannabis use and the prevalence of gastritis from diverse causes led us to perform this study. In the same light, no human study has explored the effect of concomitant alcohol and cannabis use on the risk of having alcoholic gastritis. Therefore, we examined the impact of concomitant risky alcohol and cannabis use on the prevalence of acute gastritis among hospitalized subjects.
MATERIALS AND METHODS

Study Population and Design
We analyzed discharge records of hospitalized patients (≥18 years) with a clinical history of risky alcohol consumption making use of data from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) database for 2014 ("HCUP-US NIS Overview," n.d.; Houchen et al., n.d.) . The HCUP-NIS is the largest inpatient database in the United States of America, generated and maintained by the Agency for Healthcare Research and Quality (AHRQ). AHRQ collects data from over 3,000 nonfederal hospitals across more than 30 states in the United States, to produce about 7 to 8 million records for the 2014 HCUP-NIS data used in this study. Each record contains over 30 clinical diagnoses, encoded with the International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM; World Health Organization, 2004). The HCUP-NIS is a publically available online data set which is completely de-identified. As such, our studies did not require an Institutional Review Board approval.
Selection of Variables, Cannabis Cohort, and Propensity Matching Variables
After selecting records with risky alcohol use, we next identified records with cannabis use and associated clinical characteristics ( Fig. 1 and Table S1 ). Associated variables from the data set included age, race, gender, health insurance, income quartile, region, and hospital teaching status. Gender was coded as male or female; race as White, Black, Hispanic, and others; health insurance as Medicare, Medicaid, private, and self-pay and others; and region as northeast, west, south, and midwest, based on U.S. Census Bureau. Patient income groups were categorized in 4 quartiles based on average household income of the zip code of residence. Hospital teaching status was categorized as rural, urban nonteaching, and urban teaching.
Chronic comorbidities were determined through either ICD-9-CM codes, Elixhauser comorbidity variables, or clinical classification systems (heart failure, kidney disease, ischemic heart disease, valvular heart disease, arrhythmias, hypertension, cerebral vascular disease, peripheral vascular disease, lung disease, thyroid disorders, and acquired immune deficiency syndrome, etc.). These demographics and comorbidities were used to build a logistic regression model, to predict records with cannabis use.
Our outcome variable was acute alcoholic gastritis, which was identified with ICD-9-CM codes. We and others have previously used these ICD-9-CM codes to identify alcohol and cannabis use disorders in the HCUP-NIS (Adejumo et al., 2017 (Adejumo et al., , 2018 Mamic et al., 2016; Whitman et al., 2017) .
Statistical Analysis
Continuous variables were represented with a mean (standard deviation) or median (interquartile range) using Mann-Whitney U statistical test. Categorical variables were represented with percentages and compared with Rao-Scott chi-square. Figure S1 depicts the statistical analyses performed at each step of the study.
From our study population of risky alcohol users, we identified and modeled cannabis users with a multivariate logistic regression to generate propensity scores. The propensity score was the probability of using cannabis versus not using cannabis. With a caliper less than 0.2 of the standard deviation of the logit of the propensity scores, we used a greedy match algorithm (gmatch macro) to match cannabis users to nonusers in a 1:1 ratio (Hammill, 2015) . Propensity matching is a powerful statistical methodology to eliminate selection bias, balance the covariates, and exclude a large proportion of residual confounding in observational studies, such as ours. The effects generated in propensity matching generally go in similar magnitude and direction as randomized clinical control trials (Dahabreh et al., 2012; Kitsios et al., 2015) . To accommodate the statistical effect of matching, we compared cannabis users to nonusers with paired equivalents of the tests above: paired t-test, Wilcoxon signed-rank test, and McNemar's test.
We estimated the adjusted rates per 100,000 hospitalizations (aIR) and adjusted relative risk (aRR) for having alcoholic gastritis with risky cannabis consumption, by conditional Poisson regression models, with robust modification of the error variances (Spiegelman and Hertzmark, 2005) . Additionally, we subdivided cannabis use into dependent use and nondependent use to imprecisely estimate an increasing cannabis dosage effect. Then, we re-estimated the aIR and aRR with each level of cannabis use.
We used a p-value of <0.05, reported our estimates with 95% confidence intervals (CIs), and performed all our analysis using Statistical Analysis System (SAS V.9.4, SAS Institute Inc, Cary, NC). We used GraphPad Prism 7 (San Diego, CA) for graphical representation of plotted estimates.
RESULTS
Study Population
We evaluated 316,916 complete hospitalization records with a diagnosis of current alcohol use disorder (dependent and nondependent). Of these, 5,029 had alcoholic gastritis ( Fig. 1 and Table 1 ). There was no significant difference in gender and income distribution, and frequency of tobacco use in the population with alcoholic gastritis and those without the disease. Both groups had about 70 to 72% male gender and 33 to 35% coming from the lowest income quartile. Compared to the healthy control group, individuals diagnosed with alcoholic gastritis were younger (47.96 vs. 51.48 years), Hispanic (13.84% vs. 9.89%), more like to be on Medicaid and self-pay health insurance (19.47% vs. 29.43% and 21.48% vs. 17.18%), and less likely to be in the southern region of the United States (28.28% vs. 35.87%).
Finally, those with alcoholic gastritis were less likely to use cannabis (8.01% vs. 9.73%), but more likely to be dependent on alcohol use (82.76% vs. 54.98%).
Determinants of Cannabis Use (Before and After Matching)
Among our population of risky alcohol users, concomitant cannabis users had a higher odds to be younger, of Black race, posses nonprivate health insurance, and lower income status (Table S2) . Cannabis users were less likely to depend on alcohol and to have numerous comorbidities. However, they were more likely to use tobacco and to have chronic lung diseases. After matching, a majority of these differences was either reduced or eliminated.
Multivariate Analysis of Alcoholic Gastritis
Before multivariate adjustment, the prevalence rate for having alcoholic gastritis was 20% lower among cannabis users (cRR: 0.81 [0.71 to 0.3], Table 2 ). This prevalence became more pronounced (25%) after adjustment (aRR: 0.75 [0.65 to 0.85]). The prevalence of alcohol-associated gastritis was higher with many other clinical characteristics: 290% higher with dependent alcohol usage, 15% less for every 10-year increase in age, and 27% lower in the south than in the northeastern region of the United States Table 3 ). When cannabis users were subclassified based on the level of dependence on cannabis use (dependent vs. nondependent), the prevalence of alcoholic gastritis was 44 and 22% lower among dependent and nondependent users, respectively, when compared to nonusers. Subsequently, subgroup analysis among cannabis users revealed even lower aRR among dependent users when compared to nondependent users (aRR: 0.78 [0.68 to 0.89]). Finally, another subgroup analysis involving re-classification of alcohol users (dependent and nondependent) demonstrates that the risk of alcoholic gastritis was about 400% higher among dependent risky alcohol consumers compared to nondependent users (aRR: 4.90 [4.14 to 5.80]).
DISCUSSION
Following our analysis of 316,916 patient records with a diagnosis of risky alcohol use, we provide novel population-based evidence that concomitant cannabis use is associated with a reduced risk of alcohol-associated gastritis among hospitalized individuals (Fig. 2) . Mechanistically, cannabinoids which are the main active ingredients in cannabis can suppress the development of alcoholic gastritis through multiple ways. Cannabinoid actions involving the vagus nerve center in the brain (largest neuron in the body connecting the brain to the stomach) and local factors within the stomach represent one aspect. Although still an active area of research, cannabidiol (CBD) and tetrahydrocannabinol (THC) are the most studied cannabinoids from the over 400 agents in the cannabis plant (Atakan, 2012) . They act predominantly on cannabinoid 1 and 2 receptors (CB1R and CB2R). CB1R in the brain stem inhibits the activity of the dorsal nucleus of the vagus nerves, which suppresses the vomiting center activity of the vagus nerve (Van Sickle et al., 2001 ). The vagus nerve supplies the stomach, activating gastric acid secretion, digestion, and gastric motility. The brain stem action of CB1R mediates the powerful anti-emetic and appetite-stimulating effect of cannabis (Van Sickle et al., 2001) , which has Fig. 2 . Prevalence rates of alcoholic gastritis among hospitalized patients. Alcoholic gastritis is characterized by inflammatory cell infiltration of the gastric mucosa and gastrointestinal bleeding. Our observations suggest that cannabis use by hospitalized patients with a clinical history of risky alcohol use is associated with decreased prevalence of alcohol-associated gastritis. Dependent cannabis users were least likely to develop alcoholic gastritis compared to nondependent cannabis users and problematic alcohol consumers who did not use cannabis. Illustrated schematics made use of some motifolio templates (www.motifolio.com). been extremely successful among patients with chronic disorders that cause significant vomiting and malnutrition (Parker et al., 2011) . In 1 study, the application of cannabinoids into the brain did not affect gastric acid secretion compared to intravenous administration (Adami et al., 2004) . Another study reported that the gastric mucosa was protected from alcohol-induced injury following either intravenous or intracerebroventricular injection of CB1R agonists (Shujaa et al., 2009 ). These conflicting results highlight the need for further studies to elucidate the impact of central nervous versus intravenous effects of cannabinoids on gastric acid production and mucosal integrity.
Unlike the central actions of cannabinoids discussed above, there is more consistent evidence on the gastric action of cannabinoids on alcoholic gastritis (Abdel-Salam, 2016; Abdel-Salam et al., 2015; Adami et al., 2002; Coruzzi et al., 1999; Sofia et al., 1978) . Gastritis is characterized by gastric lining inflammation and mucous secretion mediated by gastric epithelial cells, gastrin-producing cells (G cells), somatostatin-secreting cells (D cells), gastric acid-secreting cells (parietal cells), histamine-producing cells (enterochromaffin cells), gastric muscular wall, and sphincters (Abdel-Salam, 2016) . CB1R has been demonstrated on parietal cells, mucosal and submucosal blood vessels, and vagal neurons in the stomach innervating the smooth muscles. Parietal cells, the acid producers in the stomach, harbor receptors for many activating ligands including histamine, gastrin, and acetylcholine, and inhibitory ligands such as somatostatin and CB1R. Gastrin is the most potent parietal cell stimulant, and acute alcohol use triggers both gastrin production by G cells and gastric acid production from parietal cells, resulting in stomach acidosis. By triggering CB1R on parietal cells, the THC content of cannabis can suppress gastric acid production, preventing the stomach mucosa from acidic damage.
Besides suppressing gastrin and gastric acid production, cannabis, via CB1R, exerts a potent anti-inflammatory action in the stomach by inhibiting excess reactive oxygen species production, tumor necrosis factor-alpha, increasing protective mucus production, and dose-dependently protecting the stomach from alcohol and aspirin-induced gastritis (Abdel-Salam, 2016; Abdel-Salam et al., 2015; Kvietys et al., 1990) . Through similar action, murine studies have demonstrated that CB1R agonism protects the stomach from nonsteroidal anti-inflammatory drug induced gastritis (Kinsey and Cole, 2013; Kinsey et al., 2011) . Furthermore, alcohol inhibits gastric smooth muscle contraction, decreasing gastro-duodenal flow, thereby causing prolonged exposure of gastric mucosa to both the alcohol and acidic contents of the stomach (Bujanda, 2000; Kaufman and Kaye, 1979) . Likewise, CB1R activation through THC also suppresses gastric emptying similar to alcohol, theoretically prolonging the duration of contact of the gastric alcoholic content on gastric mucosa, and potentially exacerbating alcoholic gastritis (McCallum et al., 1999) . Taken together, our observations suggest that the summative actions of cannabis use on the stomach might actually be to suppress gastrin release, gastric acid secretion, and gastric mucositis, thereby suppressing gastritis.
To the best of our knowledge, our study is the first to evaluate the association of cannabis use on alcoholic gastritis in hospitalized individuals. With increasing legalization and global adoption of recreational cannabis use, the clinical impact of cannabis usage on various clinical conditions is expected to rise. Therefore, studies to understand and elucidate the true association of cannabis on the human body are urgently warranted. In this respect, further studies are needed to ascertain which cannabis strains based on their differential THC to CBD content can provide the best therapeutic benefit for gastritis due to risky alcohol use or other causes.
Strengths and Limitations
Notable weaknesses in our study include recall biases, cross-sectional design, ICD-9-CM coding and allocation errors, lack of information on the type or strain of cannabis ingested, mode of cannabis use, recall biases, and lack of information on the type/quantity of alcohol consumed or on the severity of gastritis. Other limitations include sensitivity and specificity of ICD-9-CM code for alcoholic gastritis and cannabis use disorder. Our study population was recorded with alcohol use disorder, which is only likely to be ascribed to patients with evidence of risky alcohol use and is likely to have a high specificity. The ICD-9-CM codes of alcohol use disorder might not be sensitive enough, which implies that we might have omitted some records with the disease. The ICD-9-CM code for cannabis use disorder is associated with a similar sensitivity weakness. By doing a propensity matching of cannabis users with nonusers, which is based on probability scores, we eliminated the majority of the potential selection bias and residual confounding. However, unmeasured confounding factors might not have been completely eliminated.
If errors in recall and selection biases had a similar impact on both cannabis users and nonusers group, the size of the observed associations would be diminished. Additionally, to dissuade any adverse associated polysubstance use stigmas, individuals with alcoholic gastritis might not volunteer cannabis use, which would also decrease the size of the association. Although our data are cross-sectional, both alcohol and cannabis use disorders tend to be subacute to chronic, unlike alcoholic gastritis which is an acute process. Hence, we can indirectly infer a temporal association. Finally, HCUP-NIS data allowed us to evaluate a large sample population of independent as well as concomitant risky alcohol and cannabis users. Our study population covered almost all geographic regions, economic and demographic groups in the United States. Therefore, our result might be quite generalizable of the U.S. population.
CONCLUSIONS
Our study is the first human study to evaluate the association of cannabis use on the prevalence of alcoholic gastritis in hospitalized patients. We reveal that concomitant risky alcohol drinking and cannabis use resulted in decreased likelihood of alcohol-associated gastritis. Our results require further mechanistic experimental and prospective human studies to delineate the specific effects of cannabis use on the development of alcoholic gastritis.
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